Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jan. 02, 2022
Dec. 31, 2020
Operating expenses:    
Cost of revenue $ 1,967 $ 3,375
Research and development 37,850 14,442
Selling, general and administrative 29,705 5,713
Total operating expenses 69,522 23,530
Loss from operations (69,522) (23,530)
Other income (expense):    
Change in fair value of convertible preferred stock warrants and common stock warrants (56,141) (13,789)
Issuance of convertible preferred stock warrants 0 (1,476)
Change in fair value of convertible promissory notes 0 (2,422)
Gain on extinguishment of paycheck protection program loan 0 1,628
Interest expense, net (187) (107)
Other income (expense), net (24) 46
Total other income (expense), net (56,352) (16,120)
Net loss $ (125,874) $ (39,650)
Net loss per share, basic and diluted $ (1.07) $ (0.49)
Weighted average number of common shares outstanding, basic and diluted 117,218,893 80,367,324